NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
Advertisement
NewsRx | Free Trials
Advertisement
----------
------------
NewsRx on Facebook
-----
Press Release Submissions
PR Login
*
*

Cancer Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Learn More

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now



Cancer Gene Therapy



Reports from National Institutes of Health highlight recent research in cancer gene therapy



February 17th, 2009

Researchers detail in 'Nitric oxide prodrug JS-K inhibits ubiquitin E1 and kills tumor cells retaining wild-type p53,' new data in cancer gene therapy. According to a study from the United States, "Nitric oxide (NO) is a major effector molecule in cancer prevention. A number of studies have shown that NO prodrug JS-K (O(2)-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate) induces apoptotic cell death in vitro and in vivo, indicating that it is a promising new therapeutic for cancer."

"However, the mechanism of its tumor-killing activity remains unclear. Ubiquitin plays an important role in the regulation of tumorigenesis and cell...


Source: Cancer Weekly (2009-02-17)

NewsRx Passes
Advertisement
More Articles

Related Topics

------------------------
Security by Verisign PR Login